Gilead’s HIV ART combo deemed non-inferior in second Phase III trial
Gilead Sciences’ human immunodeficiency virus (HIV) single-tablet combination antiretroviral therapy (ART) has proven non-inferior to standard of care (SoC) in a…
News
Increasing trial activity in APAC region influences commercial supply chains
Sanofi shares fall 6% after double setback for MS drug tolebrutinib
InnoCare’s BTK inhibitor advances to Phase III in SLE
Alphyn secures $25m in Series B for trial of Zabalafin Hydrogel
Anova introduces AI patient matching solution for clinical trials
Rezolute stock crashes after sole pipeline candidate fails Phase III
Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial
